Oncolys BioPharma Inc. (4588.T) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	31.5M	28.0M	31.0M	63.0M	976.0M
Cost of Revenue	—	—	—	—	—
Gross Profit	31.6M	28.5M	31.4M	30.6M	338.5M
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	1.7B	2.1B	1.7B	2.0B	1.5B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	1.7B	2.1B	1.7B	2.0B	1.5B
Cost and Expenses	1.7B	2.1B	1.7B	2.0B	2.2B
Operating Income (EBIT)	(1.7B)	(2.0B)	(1.7B)	(1.9B)	(1.2B)
Non-Operating
Interest Income	5.6M	3.9M	2.1M	1.5M	587.0K
Interest Expense	7.1M	5.2M	4.6M	3.6M	3.9M
Net Interest Income	(1.5M)	(1.3M)	(2.5M)	(2.1M)	(3.4M)
Other Non-Op Income/Expense	5.8M	(27.2M)	17.5M	16.2M	41.5M
Non-Operating Income (excl Interest)	9.5M	93.0K	43.8M	30.7M	62.7M
EBT (Pre-Tax Income)	(1.7B)	(2.1B)	(1.7B)	(1.9B)	(1.1B)
Income Tax Expense	4.3M	4.0M	3.8M	2.9M	2.9M
Bottom Line
Net Income	(1.7B)	(2.1B)	(1.7B)	(1.9B)	(1.1B)
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(1.7B)	(2.1B)	(1.7B)	(1.9B)	(1.1B)
Per Share
Basic EPS	(¥64)	(¥80)	(¥77)	(¥109)	(¥66)
Diluted EPS	(¥64)	—	—	—	—
Revenue Per Share	¥1	¥1	¥1	¥4	¥56
Shares
Basic Shares Outstanding	29.3M	25.7M	21.8M	17.8M	17.3M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	(934.8M)	(2.0B)	(1.7B)	(1.9B)	(1.2B)
D&A	242.0K	242.0K	815.0K	2.3M	914.0K
EBIT	(1.7B)	(2.0B)	(1.7B)	(1.9B)	(1.2B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026